發(fā)布時間：2018-01-31 00:45

  本文關(guān)鍵詞： 腫瘤 正電子發(fā)射斷層顯像術(shù)　出處：《中國臨床醫(yī)學(xué)影像雜志》2017年08期 　論文類型：期刊論文

【摘要】：目的:對比分析TOF-PET和PSF-PET重建技術(shù)對全身不同部位及不同大小惡性腫瘤病灶18F-FDG代謝參數(shù)的影響。資料與方法:回顧性分析多中心原發(fā)惡性腫瘤接受18F-FDG PET/CT全身掃描病例共270例,男121例,女149例,平均年齡(59.07±11.82)歲(29~87歲);體質(zhì)量指數(shù)(BMI)為23.92±3.35(16.61~34.34);胸部、腹部、盆腔及淺表部位惡性腫瘤分別為97、62、104和9例;病灶直徑(Dmax)為(4.16±2.27)cm(0.5~15.2 cm)。將PET/CT數(shù)據(jù)VUE Point HD、TOF+VUE Point HD、Sharp IR+VUE Point HD及TOF+Sharp IR+VUE Point HD分別進(jìn)行重建,其中VUE Point HD(GE Healthcare)為三維迭代重建技術(shù),Sharp IR(GE Healthcare)是基于PSF技術(shù)原理的PET圖像重建技術(shù)。應(yīng)用AW工作站PET VCAR軟件進(jìn)行圖像處理及測量18F-FDG代謝參數(shù)(SULmean、SULmax、SUVmean、SUVmax)并計算變化率(%)。應(yīng)用獨(dú)立樣本t檢驗(yàn)及One-way ANOVA分析TOF、PSF與TOF+PSF組代謝參數(shù)變化率的比較。結(jié)果:TOF和PSF對所有惡性腫瘤病灶的代謝參數(shù)均有提高,以TOF+PSF組最為顯著。對于胸部病灶,PSF對SUVmax提高的百分比明顯優(yōu)于TOF,為8.96%vs 5.26%(P0.05);對于淺表部位病灶,PSF對SULmax、SUVmean及SUVmax提高的百分比明顯優(yōu)于TOF,分別為9.22%vs 1.22%、8.56%vs 1.78%及9.33%vs 1.11%(P0.05);對于盆腔病灶,TOF對SULmax、SUVmax提高的百分比則優(yōu)于PSF,分別為18.72%vs 12.29%與20.69%vs 15.41%(P0.05);對于腹部病灶,TOF與PSF代謝指標(biāo)提高無明顯差異(P0.05)。BMI25組,TOF對SULmax、SUVmax提高的百分比也優(yōu)于PSF,分別為10.45%vs 6.16%與10.27%vs 6.43%(P0.05)。Dmax≤2.0 cm組,PSF對SUVmax提高的百分比明顯優(yōu)于TOF,為11.68%vs 4.78%(P0.05)。對于BMI25組及Dmax2.0 cm組,兩者對代謝參數(shù)的提高無明顯差異。結(jié)論 :聯(lián)合TOF+PSF組重建技術(shù)能顯著提高惡性腫瘤病灶代謝參數(shù),對于胸部、淺表部位病灶及較小病灶,PSF明顯優(yōu)于TOF;對于盆腔病灶及BMI25的患者TOF具有優(yōu)勢。
[Abstract]:Objective: to compare and analyze the effects of TOF-PET and PSF-PET reconstruction techniques on 18F-FDG metabolic parameters of malignant tumor lesions in different parts and sizes of the whole body. A total of 270 patients with multicenter primary malignant tumors underwent 18F-FDG PET/CT systemic scanning were retrospectively analyzed. There were 121 males and 149 females with an average age of 59.07 鹵11.82 years old. The body mass index (BMI) was 23.92 鹵3.35 (16.61g) and 34.34m (P < 0.05). The number of malignant tumors in chest, abdomen, pelvic cavity and superficial area were 97, 622, 104 and 9, respectively. The lesion diameter (D max) was 4.16 鹵2.27 cm ~ (?) 0. 5 ~ 15. 2 cm ~ (-1). VUE Point HD was obtained from PET/CT data. TOF VUE Point HD. Sharp IR VUE Point HD and TOF Sharp IR VUE Point HD were reconstructed respectively. Where VUE Point HD(GE Healthcare is a 3D iterative reconstruction technique. Sharp IR(GE Healthcare). AW workstation PET VCAR software is used to process images and measure 18F-FDG metabolic parameters. TOF was analyzed by independent sample t-test and One-way ANOVA. Results the metabolic parameters of all malignant tumor lesions were increased by PSF and PSF. In TOF PSF group, the percentage of SUVmax increase was significantly higher than that in TOF group (8.96 vs 5.26P0.05). For superficial lesions, the percentage of SUVmax and SUVmean were significantly higher than that of TOF (9.22 vs 1.22%, respectively). 8.56 vs 1.78% and 9.33 vs 1.11; For pelvic lesions, TOF was superior to PSF in increasing the percentage of SUVmax. The values were 18.72 vs 12.29% and 20.69 vs 15.41, respectively. There was no significant difference in metabolic indexes between TOF and PSF in abdominal lesions. The percentage of increase of SUVmax in Tofs group was higher than that in PSF group. The values were 10.45 vs 6.16% and 10.27, respectively. The percentage of SUVmax increased by PSF was significantly higher than that by TOF (11.68 vs 4.78P0.05. for BMI25 and Dmax2.0 cm group). Conclusion: in combination with TOF PSF reconstruction technique, the metabolic parameters of malignant tumors can be significantly increased, for chest, superficial lesions and small lesions. PSF was superior to TOF. It is superior to TOF in patients with pelvic lesions and BMI25.
【作者單位】： 中國醫(yī)科大學(xué)附屬盛京醫(yī)院放射科;天津市腫瘤醫(yī)院核醫(yī)學(xué)科;內(nèi)蒙古自治區(qū)人民醫(yī)院核醫(yī)學(xué)科;
【分類號】：R730.44
【正文快照】： 18氟-脫氧葡萄糖(18F-FDG)PET/CT利用圖像融合技術(shù)將PET及CT配準(zhǔn)、融合,目前廣泛的應(yīng)用于惡性腫瘤的確診、治療方案選擇、療效分析及預(yù)后分析中[1],利用不同的重建處理技術(shù)提高標(biāo)準(zhǔn)化攝取值(Standard uptake values,SUV)的準(zhǔn)確性及圖像質(zhì)量至關(guān)重要。目前臨床上PET/CT圖像重建

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 陳晉峰;;PET-CT檢查有必要嗎?[J];抗癌之窗;2012年11期

相關(guān)碩士學(xué)位論文 前2條

1 卜文哲;DynaCT在肝癌TACE術(shù)中的臨床應(yīng)用價值[D];濟(jì)南大學(xué);2015年

2 張萌帆;錐形束CT掃描判斷肝腫瘤病灶與供血動脈的臨床應(yīng)用與價值[D];鄭州大學(xué);2016年

，

本文編號：1477701